Improvement of work productivity and quality of life with anti-tumor necrosis factor treatment used in crohn's disease in routine clinical practice in Turkey
| Autor: | ATUĞ, ÖZLEN |
|---|---|
| Přispěvatelé: | TÖRÜNER M., BAŞARANOĞLU M., ATUĞ Ö., Senturk O., Akyuz F., Cekic C., Over Hamzaoglu H., Tekin F., Sezgin O., AKPINAR H., et al. |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Internal Diseases
Gastroenterology and Hepatology Sağlık Bilimleri İç Hastalıkları Clinical Medicine (MED) Anti-TNF CERTOLIZUMAB PEGOL Gastroenteroloji-(Hepatoloji) Health Sciences INFLIXIMAB Klinik Tıp (MED) OUTCOMES Internal Medicine Sciences Klinik Tıp GASTROENTEROLOGY & HEPATOLOGY Gastroenterology Dahili Tıp Bilimleri REMISSION CLINICAL MEDICINE work productivity GASTROENTEROLOJİ VE HEPATOLOJİ Tıp Gastroenteroloji Crohn's disease MAINTENANCE quality of life Medicine MODERATE ACTIVITY IMPAIRMENT QUESTIONNAIRE TRIAL INFLAMMATORY-BOWEL-DISEASE ADALIMUMAB |
| Popis: | BACKGROUND: Patients with Crohn\"s disease experience major deterioration in work productivity and quality of life. We aimed to provide the long-term effects of anti-tumor necrosis factor agents on work productivity and activity impairment and quality of life in patients with Crohn\"s disease using the Inflammatory Bowel Disease Questionnaire and the Short-Form Health Survey-36. METHODS: Patients with Crohn\"s disease and initiated an anti-tumor necrosis factor treatment were included and followed up for 12 months in this observational study. RESULTS: A total of 106 patients were included in this study, and 64.2% of the patients were males. Mean [± standard deviation] age was 36.8 [± 10.9] years. At baseline, mostly perianal fistulas [65.7%] were observed [n = 23]. Intestinal stenosis was detected in 34.9% of the patients [n = 37], and most of the stenosis was located in the ileum [70.6%] followed by the colon [20.6%]. Extraintestinal symp- toms were observed in 24 patients [22.6%]. Most frequent extraintestinal symptom was arthritis with 71.4% [n = 15]. Mean time from first symptom to initiation of anti-tumor necrosis factor treatment was 6.3 [± 5.0] years. Improvements in work productivity and activ- ity impairment scores throughout 12 months were -24.1% [P = .003] for work time missed, -18.0% [P = .006] for impairment at work, -8.5% [P = .160] for overall work impairment, and -17.0% [P < .001] for daily activity impairment. Similarly, significant improvements [P < .001] were detected in all components of the Inflammatory Bowel Disease Questionnaire when compared to baseline. Statistically sig- nificant improvements [P < .05] were detected for all components of Short-Form Health Survey-36 except for mental health [P = .095]. CONCLUSION: Our study indicates the significant improvement in work productivity and activity impairment and quality of life of patients with Crohn\"s disease who receive long-term anti-tumor necrosis factor treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|